Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytot...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386616/ |